MEDBOT-B (02252) announced its performance for the year 2025, with a net loss attributable to shareholders of 250 million yuan, a 61.1% decrease compared to the previous year.

MEDBOT-B(02252) released its annual performance as of December 31, 2025, with revenue of 551 million yuan, a year-on-year increase of 114.2%; the net loss attributable to equity shareholders of the company was 250 million yuan, a year-on-year decrease of 61.1%; basic loss per share was 0.24 yuan. The increase in revenue during the period was mainly attributed to the breakthrough progress in the commercialization of the core product "TuMai endoscopic surgery" by Siasun Robot&Automation, with rapid sales growth. In particular, the overseas market expansion of TuMai showed significant results, with over a hundred new orders from overseas markets throughout the year and overseas market sales revenue exceeding five times that of the previous year. The growth rate far exceeded the industry average, demonstrating strong global expansion momentum.